SLC5A2 and type 2 diabetes mellitus: The DISCOVER study, which assessed global trends in SGLT2 inhibitor and GLP-1 RA prescriptions in more than 14,000 patients with T2DM from 37 countries, reported an increase in SGLT2 inhibitor and GLP-1 RA use from 10.8% to 16.1% over 8 years [11].